← Leaderboards
John M Ringman
University Of Southern California
$18,719,928
Attributed
$27,290,536
Total exposure
33
Grants
23
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.1M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$29,238,898 · 34
By mechanism
U01$7,454,294 · 2
R01$7,363,396 · 2
P50$4,341,417 · 2
UH3$3,991,163 · 1
UF1$2,623,751 · 1
UH2$2,381,301 · 1
Top collaborators
- Amir H Kashani9 shared
- Danny Jiong Jiong Wang9 shared
Most similar at University Of Southern California
Same institution · by research overlap
- Amir H Kashani$11,509,148
- Danny Jiong Jiong Wang$29,986,445
- Mara Mather$20,093,585
- Grace Marie Richter$983,917
- Xuejuan Jiang$4,011,181
Others in their field
Top investigators on “S Disease”
- Lawrence Corey · Fred Hutchinson Cancer Center$643,566,627
- Jeffrey P Krischer · University Of South Florida$588,279,843
- Bambra Strokes · Ppd Development Lp$526,656,217
- Judith S. Currier · University Of California Los Angeles$477,614,997
- David Heimbrook · Leidos Biomedical Research, Inc.$470,438,912
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$389,132,404
Research focus
S DiseaseAlzheimer&AposResearch PersonnelPersonsBiological MarkersMexicanCognitiveFundingUnited States National Institutes Of HealthImageMutationProtocols DocumentationPresenilin-1BaseClinical ResearchResourcesCohortDementiaUniversitiesEvaluationImpaired CognitionGeneticGrantDensity
Grant awards (60)
Validation of Imaging and Blood-based Small Vessel VCID Biomarkers in Multiethnic Population$1,282,792
U01 · FY2025 · NS
Validation of Imaging and Blood-based Small Vessel VCID Biomarkers in Multiethnic Population$1,286,604
U01 · FY2024 · NS
Phenotype and Genotype of Autosomal Dominant Alzheimer's Disease in Jalisco, Mexico$632,298
R01 · FY2024 · AG · contact PI
Validation of Imaging and Blood-based Small Vessel VCID Biomarkers in Multiethnic Population$1,290,301
U01 · FY2023 · NS
Motor, Visual, and Olfactory Changes in Genetic Subtypes of Alzheimerâs Disease$820,753
R01 · FY2023 · AG · contact PI
Phenotype and Genotype of Autosomal Dominant Alzheimer's Disease in Jalisco, Mexico$631,599
R01 · FY2023 · AG · contact PI
Motor, Visual, and Olfactory Changes in Genetic Subtypes of Alzheimerâs Disease$820,753
R01 · FY2022 · AG · contact PI
Phenotype and Genotype of Autosomal Dominant Alzheimer's Disease in Jalisco, Mexico$651,302
R01 · FY2022 · AG · contact PI
Validation of Imaging and Blood-based Small Vessel VCID Biomarkers in Multiethnic Population$2,623,751
UF1 · FY2021 · NS
Motor, Visual, and Olfactory Changes in Genetic Subtypes of Alzheimerâs Disease$820,753
R01 · FY2021 · AG · contact PI
Phenotype and Genotype of Autosomal Dominant Alzheimer's Disease in Jalisco, Mexico$657,994
R01 · FY2021 · AG · contact PI
Imaging Cerebral and Retinal Microvasculature in Cerebral Small Vessel Disease$1,530,150
UH3 · FY2020 · NS
Motor, Visual, and Olfactory Changes in Genetic Subtypes of Alzheimerâs Disease$820,753
R01 · FY2020 · AG · contact PI
Phenotype and Genotype of Autosomal Dominant Alzheimer's Disease in Jalisco, Mexico$682,193
R01 · FY2020 · AG · contact PI
Imaging Cerebral and Retinal Microvasculature in Cerebral Small Vessel Disease$1,230,507
UH3 · FY2019 · NS
Motor, Visual, and Olfactory Changes in Genetic Subtypes of Alzheimerâs Disease$824,998
R01 · FY2019 · AG · contact PI
Imaging Cerebral and Retinal Microvasculature in Cerebral Small Vessel Disease$1,230,506
UH3 · FY2018 · NS
The structural and functional connectome across Alzheimer's disease subtypes$964,413
U01 · FY2018 · AG · contact PI
Imaging Cerebral and Retinal Microvasculature in Cerebral Small Vessel Disease$1,191,714
UH2 · FY2017 · NS
The structural and functional connectome across Alzheimer's disease subtypes$963,951
U01 · FY2017 · AG · contact PI
Imaging Cerebral and Retinal Microvasculature in Cerebral Small Vessel Disease$1,189,587
UH2 · FY2016 · NS
The structural and functional connectome across Alzheimer's disease subtypes$962,134
U01 · FY2016 · AG · contact PI
The structural and functional connectome across Alzheimer's disease subtypes$704,099
U01 · FY2015 · AG · contact PI
CLINICAL CORE$457,995
P50 · FY2014 · AG · contact PI
Establishing Infrastructure for Prevention of familial AD in Mexico$65,016
R21 · FY2014 · TW · contact PI
Establishing Infrastructure for Prevention of familial AD in Mexico$47,984
R21 · FY2014 · TW · contact PI
Establishing Infrastructure for Prevention of familial AD in Mexico$33,759
R21 · FY2014 · TW · contact PI
CLINICAL CORE$429,810
P50 · FY2013 · AG · contact PI
Establishing Infrastructure for Prevention of familial AD in Mexico$79,241
R21 · FY2013 · TW · contact PI
CLINICAL CORE$526,084
P50 · FY2012 · AG · contact PI
CLINICAL CORE$505,129
P50 · FY2011 · AG · contact PI
UCLA Alzeheimer's Disease Research Center$1,948,362
P50 · FY2010 · AG · contact PI
CLINICAL CORE$474,037
P50 · FY2010 · AG · contact PI
BEHAVIORAL AND NEUROCHEMICAL CORRELATES OF PRESENILIN-1 MUTATION STATUS$21,096
M01 · FY2010 · RR · contact PI
BEHAVIORAL AND NEUROCHEMICAL CORRELATES OF PRESENILIN-1 MUTATION STATUS$18,102
M01 · FY2009 · RR · contact PI
A PHASE II, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY AND TOLERABIL$431
M01 · FY2009 · RR · contact PI
BEHAVIORAL AND NEUROCHEMICAL CORRELATES OF PRESENILIN-1 MUTATION STATUS$41,352
M01 · FY2008 · RR · contact PI
A PHASE II, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY AND TOLERABIL$10,338
M01 · FY2008 · RR · contact PI
EVALUATION OF THE SAFETY, TOLERABILITY AND IMPACT ON BIOMARKERS OF ANTI-OXIDA$2,495
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: -K$362
M01 · FY2008 · RR · contact PI
A PHASE II, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY AND TOLERABIL$43,273
M01 · FY2007 · RR · contact PI
BEHAVIORAL AND NEUROCHEMICAL CORRELATES OF PRESENILIN-1 MUTATION STATUS$35,374
M01 · FY2007 · RR · contact PI
EVALUATION OF THE SAFETY, TOLERABILITY AND IMPACT ON BIOMARKERS OF ANTI-OXIDA$9,960
M01 · FY2007 · RR · contact PI
-K$5,839
M01 · FY2007 · RR · contact PI
HIGH DOSE SUPPLEMENTS TO REDUCE HOMOCYSTEINE AND SLOW THE RATE OF COGNITIVE$2,404
M01 · FY2007 · RR · contact PI
BEHAVIORAL AND NEUROCHEMICAL CORRELATES OF PRESENILIN-1 MUTATION STATUS$72,870
M01 · FY2006 · RR · contact PI
A PHASE II, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY AND TOLERABIL$68,066
M01 · FY2006 · RR · contact PI
K$12,012
M01 · FY2006 · RR · contact PI
HIGH DOSE SUPPLEMENTS TO REDUCE HOMOCYSTEINE AND SLOW THE RATE OF COGNITIVE$5,205
M01 · FY2006 · RR · contact PI
DEPRESSION IN ALZHEIMER'S DISEASE (DAD)$3,203
M01 · FY2006 · RR · contact PI
TREATMENT OF AGITATION/PSYCHOSIS IN DEMENTIA/PARKINGSONISM (TAP/DAP)$801
M01 · FY2006 · RR · contact PI
FMRI in Pre-Symptomatic PS1-related Alzheimer's Disease$160,561
K08 · FY2005 · AG
K$10,972
M01 · FY2005 · RR
A PHASE II, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY AND TOLERABIL$6,352
M01 · FY2005 · RR
HIGH DOSE SUPPLEMENTS TO REDUCE HOMOCYSTEINE AND SLOW THE RATE OF COGNITIVE$3,465
M01 · FY2005 · RR
DEPRESSION IN ALZHEIMER'S DISEASE (DAD)$2,310
M01 · FY2005 · RR
TREATMENT OF AGITATION/PSYCHOSIS IN DEMENTIA/PARKINGSONISM (TAP/DAP)$288
M01 · FY2005 · RR
FMRI in Pre-Symptomatic PS1-related Alzheimer's Disease$160,561
K08 · FY2004 · AG
FMRI in Pre-Symptomatic PS1-related Alzheimer's Disease$149,843
K08 · FY2003 · AG
FMRI in Pre-Symptomatic PS1-related Alzheimer's Disease$10,041
K08 · FY2003 · AG